# CalciMedica, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/CalciMedica, Inc.).

## Overview

CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious inflammatory and immunologic diseases driven by calcium signaling and direct cellular injury. Its core scientific focus is inhibition of calcium release-activated calcium, or CRAC, channels, which the company believes could create a new class of therapeutics. The lead program is Auxora, an intravenously formulated small-molecule CRAC channel inhibitor containing zegocractin, which has been studied in acute critical care settings such as acute pancreatitis, severe COVID-19 pneumonia, pediatric asparaginase-induced pancreatic toxicity, and acute kidney injury with acute hypoxemic respiratory failure. The company is still in development mode, has no approved products, and is working toward a potential pivotal program in acute pancreatitis while relying on external capital and contract manufacturers.

## Products & services

• Auxora (zegocractin) IV CRAC channel inhibitor
• CRAC channel inhibitor platform for inflammatory diseases
• Clinical development in acute pancreatitis
• Clinical development in acute critical care indications
• Preclinical/early-stage pipeline around immune-mediated injury

- **Lead clinical asset: Auxora** (100%) — Auxora is the company's lead IV small-molecule CRAC channel inhibitor being developed for acute inflammatory and tissue-injury settings.
- **CRAC channel inhibitor platform** (0%) — The platform includes discovery and development of therapies that modulate CRAC channel signaling across multiple indications.
- **Clinical development programs** (0%) — This includes Phase 2 and planned pivotal clinical work in acute pancreatitis and other critical care indications.
- **Preclinical and translational research** (0%) — Earlier-stage work supporting new indications and mechanism validation for CRAC inhibition.

- Auxora (zegocractin), an intravenous CRAC channel inhibitor
- CRAC channel inhibitor platform targeting inflammatory signaling
- Acute pancreatitis clinical development program
- Critical care programs in severe inflammatory lung and kidney injury
- Preclinical and exploratory development for additional indications

## Customers

CalciMedica does not yet have commercial customers because it has no approved products or product sales. Its current 'customers' are primarily clinical trial investigators, hospitals, and research sites that enroll patients in its studies, along with regulators such as the FDA that determine whether its programs can advance. If Auxora or another candidate is approved, the eventual buyers would likely be hospitals, critical care physicians, and health systems treating acute inflammatory conditions. The company may also pursue collaboration partners in the pharmaceutical industry to help fund development or support future commercialization.

- **Clinical trial sites and investigators** (primary) — Hospitals and research centers that run Auxora trials and generate the clinical data needed for regulatory advancement.
- **Regulatory agencies** (primary) — The FDA and other regulators that review trial design, safety, and efficacy before any commercialization can occur.
- **Potential hospital buyers** (emerging) — If approved, hospitals and health systems would buy Auxora for acute care use in serious inflammatory conditions.
- **Pharmaceutical collaborators** (secondary) — Potential partners that may provide funding, development support, or commercialization capabilities.

- Hospitals and clinical trial sites enrolling patients in Auxora studies
- Critical care physicians treating acute pancreatitis and related conditions
- Regulators such as the FDA that gate program advancement
- Potential pharmaceutical collaborators for development or commercialization
- Future hospital and health-system buyers if a product is approved

## Geography

CalciMedica is headquartered in La Jolla, California, and its operations are centered in the United States. The company’s development work depends on U.S.-based management, regulatory engagement, and clinical trial execution, although future trials or collaborations could extend into other regions. Manufacturing is outsourced to contract manufacturing organizations rather than owned facilities, so geography matters mainly through the location and resilience of third-party suppliers and clinical sites. The company also highlights exposure to global health, geopolitical, tariff, and trade-related disruptions that could affect trials, collaborators, and supply chains.

- Headquartered in La Jolla, California, United States
- Primary regulatory and corporate activity is U.S.-based
- Clinical development is centered on U.S. trial and FDA interactions
- Manufacturing is outsourced to third-party CMOs rather than owned plants
- Global supply-chain and geopolitical disruptions can affect trial execution

## Strategy

The company’s near-term strategy is to advance Auxora in acute pancreatitis and finalize the design of a potential pivotal program with the FDA in the first half of 2026. Because it has no commercial infrastructure, CalciMedica is focused on clinical development, regulatory alignment, and preserving capital rather than building a sales force today. It expects to continue relying on third-party manufacturers and may consider collaborations with larger pharmaceutical companies to strengthen development and future commercialization capabilities. The company also needs to secure substantial additional financing to fund ongoing trials, regulatory work, and eventual commercialization if approval is achieved.

- **Finalize pivotal program design for acute pancreatitis** (short-term) — A clear FDA-aligned pivotal path is necessary to move Auxora from Phase 2 evidence toward potential approval.
- **Secure additional financing** (short-term) — The company states current cash is insufficient to fund development through approval, making capital access essential.
- **Expand development through partnerships** (medium-term) — Collaborations could provide non-dilutive funding, development expertise, and future commercialization support.

- Advance Auxora in acute pancreatitis toward pivotal development
- Work with the FDA on pivotal trial design and regulatory path
- Preserve cash while operating as a clinical-stage company
- Use external CMOs instead of building internal manufacturing
- Consider partnerships to expand development and commercialization capacity
- Raise additional capital to fund trials and future launch activities

## Risks

CalciMedica faces the classic risks of a clinical-stage biotech: it has no product revenue, a limited operating history, and a high probability of continued losses until a product is approved. Its lead asset, Auxora, still depends on clinical success and regulatory acceptance in acute pancreatitis, so any safety, efficacy, or trial-design setback could materially delay or end the program. The company also depends on external capital, and management has disclosed substantial doubt about its ability to continue as a going concern, which makes financing risk especially important. More broadly, competition from better-funded drug developers, dependence on third-party manufacturers and clinical sites, and supply-chain or geopolitical disruptions could all impair development timelines and increase costs.

- **Clinical development failure for Auxora** [critical] — The company’s value is concentrated in a single lead asset that must prove safety and efficacy in pivotal studies.
- **Going-concern and financing risk** [critical] — Management disclosed that current cash may not fund operations for the next year and that substantial additional capital is required.
- **Regulatory risk** [high] — The FDA may require additional data, different endpoints, or larger trials before approval can be pursued.
- **Third-party manufacturing and trial execution risk** [high] — The company relies on CMOs and external research organizations rather than owning manufacturing or trial infrastructure.
- **Competitive risk** [medium] — Other companies may develop more effective, safer, or faster-to-market treatments for the same indications.

- No approved products means no product revenue and continued dependence on capital markets
- Clinical failure or weak data for Auxora could eliminate the lead value driver
- FDA feedback could require trial redesign, delaying pivotal development
- Going-concern risk reflects limited cash relative to development needs
- Dependence on CMOs and CROs creates execution and quality-control risk
- Competition from other therapies could reduce future market opportunity
- Supply-chain, geopolitical, and trade disruptions can affect trials and manufacturing

## Accounting

As a clinical-stage biotech, CalciMedica’s reported results are dominated by research and development spending rather than revenue recognition. The company has no product sales, so investors should focus on how clinical trial costs, CRO fees, manufacturing batches, and consultant spending flow through R&D expense and how those costs vary by quarter depending on trial timing. Management also highlights estimates and judgments in accruals, including accounts payable and accrued expenses, which can materially affect period-to-period operating loss and cash burn. Because the company is public and still pre-commercial, stock-based compensation, financing costs, and going-concern disclosures are also important to interpret reported results and dilution risk.

- **Research and development cost accruals** — Can materially shift quarterly operating loss and liabilities
- **Going-concern assessment** — Affects investor assessment of liquidity and solvency
- **Stock-based compensation** — Impacts reported losses and dilution analysis
- **Financing and debt/equity issuance accounting** — Affects cash flow, dilution, and financing-related expenses

- No product revenue yet, so operating results are driven by R&D and G&A expense
- Clinical trial and CMO costs can create quarter-to-quarter expense volatility
- Accrued expenses and payables require judgment and affect reported cash burn
- Stock-based compensation is important for a pre-commercial public biotech
- Financing transactions can create dilution and non-operating accounting effects
- Going-concern disclosure signals material uncertainty in financial statement presentation

---

*Last updated: 2026-04-28T14:25:12.937135+00:00*